Natco Pharma receives the cancer drug boost

Natco Pharma touched a high of Rs 134 and a low of Rs 124. The stock finally ended with a 5.2% at Rs 129. Around 2.96 lakh shares were traded on the BSE as against the two-week average trade of 1.06 lakh shares.
__________________________________________________
(Updated at 1046 hrs)

Natco Pharma has raced ahead on receiving the green signal to launch the cancer drug, Albupax. The stock is trading at Rs 130, stronger by Rs 8 or 6.5%, on the BSE. A total of 1.67 shares were traded on the BSE as against the 2-week average of 1.06 lakh shares.

The government stayed the Drug Controller of India order suspending the drug for not passing the test measuring endotoxin levels.

Albupax is a nanatechnology-based drug. It consists of paclitaxel in an Albumin-bound nanoparticle form and is used in the treatment of breast cancer.